The biotech arena is abuzz with the sizzle of weight-loss drugs—projected to burgeon at a blistering compound annual rate of 45.7% to a whopping $82.8 billion by 2032, as per DataHorizzon Research. In this piece, we’ll size up the future of two stocks vying in this pulsating market.

Eli Lilly, a biotech firm, has sparked Wall Street’s and investors’ interest with its weight-loss drugs, Mounjaro and Zepbound, pitting them against Novo Nordisk’s Wegovy and Ozempic.

The Case for Amgen Stock

Founded in 1980, Amgen boasts a diverse product portfolio spanning from oncology, hematology, cardiovascular diseases, inflammation, and bone health to general medicine. So far in 2024, Amgen’s stock has dipped 0.3%.

In the obesity market, the company has now ventured with its anti-obesity candidate called MariTide. Amgen is set to report Phase 2 clinical trial data in late 2024, with results from 592 patients.

The Case for Eli Lilly Stock

Eli Lilly stock has shown a 30% return so far in 2024, surpassing the S&P 500’s 5% gain.